NCT03045406

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,170 (actual)
• Sponsor: Fadoi Foundation, Italy · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study

Conditions

• Venous Thromboembolism

Interventions

Type	Name	Description
DRUG	Apixaban	Tablets
DRUG	Dalteparin	Injections

Timeline

• Start date: 2017-04-13
• Primary completion: 2019-06-01
• Completion: 2019-12-01
• First posted: 2017-02-07
• Last updated: 2025-06-24
• Results posted: 2025-06-18

Locations

127 sites across 11 countries: United States, Belgium, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom

Regulatory

• FDA-regulated drug study